Research and Markets has announced the addition of the "Rhino-Conjunctivitis Global Clinical Trials Review, H2, 2016" report to their offering.

The clinical trial report provides an overview of Rhino-Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Rhino-Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Scope of the Report:

  • The report provides a snapshot of the global clinical trials landscape;
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status;
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company;
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment;
  • The Report provides enrollment trends for the past five years;
  • Report provides latest news for the past three months.

Reasons to buy:

  • Assists in formulating key business strategies with regards to investment;
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost;
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities;
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market;
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted trials;
  • Facilitates clinical trial assessment of the indication on a global, regional and country level.

Companies Mentioned:

  • ALK-Abello A/S
  • Circassia Pharmaceuticals Plc
  • Laboratorios LETI SL
  • Merck KGaA
  • Stallergenes Greer plc
  • Merck & Co Inc
  • Droege International Group AG
  • Inflamax Research Inc

For more information about this report visit http://www.researchandmarkets.com/research/l72ndc/rhinoconjunctivit